文献速递生殖医学

经皮睾酮治疗对卵巢储备功能减退女性生活质量的影响:随机对照试验二次分析

The impact of transdermal testosterone treatment on quality of life in women with diminished ovarian reserve: secondary analysis of a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2026-01-01

该研究为双盲安慰剂对照随机试验的预设二次分析,纳入213例符合博洛尼亚标准的卵巢储备功能减退(DOR)女性,随机接受经皮睾酮5.5 mg/日或安慰剂治疗约60天。结果显示,睾酮组与安慰剂组在FertiQoL总分及核心、治疗等子量表上均无显著差异,校正后F(1,204)=0.07,P=0.79。

要点

  • 经皮睾酮5.5 mg/日治疗9周未改善DOR女性的生育相关生活质量。
  • 睾酮组治疗结束时总睾酮水平显著高于安慰剂组(3.2±2.7 vs 0.6±0.4 nmol/l,P<0.001)。
  • 现有证据不支持将睾酮用于改善绝经前女性的幸福感或生活质量。

核心结论

  • 在DOR女性中,经皮睾酮5.5 mg/日治疗未比安慰剂更有效改善生育相关生活质量。

研究设计与样本

  • 双盲安慰剂对照随机试验的预设二次分析,共纳入288例参与者,其中213例完成治疗前后生活质量问卷并纳入分析。
  • 参与者为18-43岁、符合博洛尼亚标准的DOR女性,计划在西班牙、比利时和丹麦的8家生殖中心接受IVF治疗。
  • 随机接受1%经皮睾酮凝胶5.5 mg/日(n=106)或相同安慰剂(n=107),在开始卵巢刺激前中位应用60天。

主要发现

  • 睾酮组与安慰剂组基线特征无显著差异。
  • 校正年龄、BMI、产次、IVF史和基线FertiQoL评分后,睾酮组与安慰剂组在FertiQoL总分上无显著差异(F(1,204)=0.07,P=0.79),核心评分、治疗评分及所有子量表亦无显著差异。
  • 治疗结束时睾酮组总睾酮水平显著高于安慰剂组(3.2±2.7 nmol/l vs 0.6±0.4 nmol/l,P<0.001)。

关键数值与推荐

  • DOR诊断依据博洛尼亚标准。
  • 生活质量评估使用FertiQoL量表,在干预前和干预完成时(卵巢刺激开始前)进行。
  • 主要分析采用单因素ANCOVA,校正年龄、BMI、产次、IVF治疗史和基线FertiQoL评分。

临床怎么用

  • 对于DOR女性,不应期望经皮睾酮治疗能改善生育相关生活质量。
  • 临床决策中,睾酮不应被视为低幸福感或低生活质量的治疗方法。

局限性

  • 生活质量为次要结局,且参与者并非基于低生活质量招募。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does transdermal testosterone treatment improve fertility-related quality of life (QOL) in women with diminished ovarian reserve (DOR)? SUMMARY ANSWER: Transdermal testosterone for 9 weeks at a dose of 5.5 mg per day did not result in improved fertility-related QOL compared with placebo in women with DOR. WHAT IS KNOWN ALREADY: Reduced QOL is prevalent in women with infertility, many of whom have DOR. Several studies have shown a correlation between DOR and lower testosterone levels, and testosterone is frequently prescribed to women with DOR undergoing fertility treatment. Some studies have reported that testosterone therapy may improve wellbeing in pre- and post-menopausal women, though others have found no benefit. There are no studies evaluating the effect of testosterone on QOL in women undergoing fertility treatment. STUDY DESIGN, SIZE, DURATION: Pre-planned secondary analysis of a double-blind placebo-controlled randomized controlled trial that included 288 participants recruited between April 2015 and August 2022. Of these, 213 completed QOL surveys both before and after treatment and were eligible for inclusion in this analysis. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Participants were women aged 18-43 years with DOR according to the Bologna criteria and planning to undergo IVF treatment at one of eight fertility clinics in Spain, Belgium, and Denmark. Participants were randomized to 5.5 mg of transdermal testosterone per day as 1% gel (n = 106) or an identical placebo (n = 107), applied for a median of 60 days prior to commencing ovarian stimulation. QOL was assessed using the FertiQoL instrument prior to commencing the intervention, and at the completion of the intervention but prior to commencing ovarian stimulation. QOL scores were compared using a one-way ANCOVA adjusted for age, BMI, parity, history of IVF treatment, and baseline FertiQoL scores. MAIN RESULTS AND THE ROLE OF CHANCE: There were no significant differences in baseline characteristics between the testosterone (n = 106) and placebo (n = 107) groups. After adjustment, testosterone showed no benefit over placebo for the Total FertiQoL score (F(1,204)=0.07, P = 0.79), the Core and Treatment scores, nor for any of the included FertiQoL subscales. Total testosterone levels were higher in the testosterone group than the placebo group at the end of the treatment (3.2 ± 2.7 nmol/l vs 0.6 ± 0.4 nmol/l, P < 0.001). LIMITATION, REASONS FOR CAUTION: QOL was a secondary outcome in this trial, and participants were not recruited based on a low QOL. WIDER IMPLICATIONS OF THE FINDINGS: Considering the available evidence, including the current study, premenopausal women are unlikely to benefit from testosterone treatment with regard to wellbeing and QOL. This study provides further evidence that testosterone should not be seen as a treatment for low wellbeing or QOL. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by unrestricted grants and support from Besins Healthcare, Roche Diagnostics, and Ferring Pharmaceuticals. The study medication and placebo were provided by Besins Healthcare. Funders had no access to patient data and had no role in the interpretation of the data, nor in the writing or approval of the final manuscript. The researchers were independent of the funders and had full access to all the data in the study. S.J.L. has received honoraria from Merck, Organon, and Hologic, consulting fees from Merck, and travel support from Merck, Organon, Besins Healthcare, and Ferring Pharmaceuticals. S.R.D. has received grants from NHMRC Australia, MS Australia, MRFF Australia, the Australian Heart Foundation, and Lawley Pharmaceuticals, consulting fees from Besins Healthcare, Astellas, and Abbott, honoraria from Theramex, Astellas, and Bayer, travel support from Astellas, and drugs/placebo from Lawley Pharmaceuticals for clinical trials; she is an Executive Board Member of the Australian Academy of Health and Medical Sciences. C.B. has received honoraria from Ferring Pharmaceuticals, IBSA, Organon, Merck A/S, and Abbott. A.G. has received honoraria from Lab Seid and travel support from Merck Serono. P.H. has received honoraria from Merck, IBSA, Gedeon Richter, and Besins Healthcare. L.D.L.F. has received consulting fees from Gedeon Richter, Ferring Pharmaceuticals, and Organon, travel support (personal and to institution) from Gedeon Richter, Ferring Pharmaceuticals, IBSA, Merck, Organon, and Theramex, and educational support (to institution) from Gedeon Richter and Merck. A.P. has received grants from Gedeon Richter, Ferring Pharmaceuticals, and Merck A/S, consulting fees from Gedeon Richter and Ferring Pharmaceuticals, honoraria from Ferring Pharmaceuticals, Gedeon Richter, Merck A/S, Abbott, and Organon, and travel support from Gedeon Richter. D.S. has received grants from Organon, Ferring Pharmaceuticals, Besins Healthcare, Gedeon Richter, and Vitrolife, honoraria from Organon, Ferring Pharmaceuticals, Besins Healthcare, Gedeon Richter, and Merck, travel support from Organon, Ferring Pharmaceuticals, Besins Healthcare, Gedeon Richter, and Merck, and is President of the Belgian Society for Reproductive Medicine. N.P.P. has received grants from Merck Serono, Ferring Pharmaceuticals, Theramex, Organon, Besins Healthcare, and Gedeon Richter, consulting fees from Merck Serono, Besins Healthcare, Organon, IBSA, FertilAI, and Alife, and honoraria from Merck Serono, Theramex, IBSA, Ferring Pharmaceuticals, Organon, Roche Diagnostics, and Besins Healthcare. S.G.M., F.M., and F.F. have no interests to declare. TRIAL REGISTRATION NUMBER: NCT02418572 (ClinicalTrials.gov).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Leathersich SJ, Davis SR, García Martínez S, et al. The impact of transdermal testosterone treatment on quality of life in women with diminished ovarian reserve: secondary analysis of a randomized controlled trial. Hum Reprod. 2026. PMID: 41461161. doi:10.1093/humrep/deaf233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。